The world is progressing towards a vaccine for the coronavirus with multiple large-scale and properly controlled studies exploring the efficacy of hydroxychloroquine, Novartis AG (NYSE: NVS) CEO Vas Narasimhan said on CNBC.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.Narasimhan said ongoing studies consist of giving doses of hydroxychloroquine to hospitalized patients and other people who may have been exposed to the coronavirus. The trials are moving at a rapid pace, including a Novartis-sponsored study and other investigative trials and “a lot more data” should come out within the following month.Narasimhan said it’s already known from pre-clinical studies involving animals so far have shown that hydroxychloroquine is “quite active against the coronavirus.”